Cost-utility analysis of Lenvatinib vs. Sorafenib in unresectable hepatocellular carcinoma in Iran
Lenvatinib is a cost-effective alternative to Sorafenib for uHCC treatment in Iran, providing better clinical outcomes and cost savings. These results support its adoption as the preferred treatment, emphasizing the importance of integrating cost-effectiveness analyses into healthcare decision-making.
Authors
- Neshaut Mashreghi Mohammadi (ORCID: https://orcid.org/0000-0002-8978-343X)
- Behzad Fatemi (ORCID: https://orcid.org/0000-0001-7912-7546)
- Mohammad Mahdi Raeis Zadeh (ORCID: https://orcid.org/0000-0003-3577-9635)
- Fatemeh Soleymani
Institutions
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1080/14737167.2025.2543465
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00